NorthWest Biotherapeutics Inc (NWBO)

[Chiugray]

And mutated IDH goes with younger age, better prognosis, and a pro-neural signature. But we are only talking about roughly 5% of the GBM population (the 5% that will no longer be called GBM).

Thanks for the great explanation. Could this 5% be correlated with the overall survival stat of roughly 5% for GBM patients alive at 5 years? I'm thinking, 95% of GBM patients never had an effective treatment. If for all of this time, the SOC (surgery, radiation, chemo) only worked on 5% of the GBM patient population (now no longer GBM LOL), then the narrative for a successful DCVAX-L is very different. DCVAX-L would be a first ever effective SOC treatment, period, not a replacement SOC.

Also, if the reason the current SOC works on the 5% only is because IDH mutant makes cancer cells more susceptible to chemo and not the case for the 95% (mesenchymal, primarily IDH wild type), then maybe the we can do away with chemo altogether for the 95% of GBM patients.